Matt I. Gross
YOU?
Author Swipe
View article: Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 113K, Supplementary Figure S7. Oral dosing of CB-839 results in high exposure in mouse plasma and is well tolerated in immunocompromised mice.
View article: Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 100K, Supplementary Figure S6. The basal glutamate to glutamine ratio and the fold change in glutamine and glutamate following CB-839 treatment is greater in TNBC cells than receptor-positive cell lines.
View article: Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 246K, Supplementary Materials and Methods.
View article: Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 85K, Supplementary Figure S5. Induction of apoptotic cell death by CB-839.
View article: Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDf - 136K, Supplementary Figure S1. CB-839 is a non-competitive inhibitor of rHu-GAC.
View article: Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 125K, Supplementary Figure S4. Markers of glutamine utilization are increased in TNBC cell lines relative to receptor-positive cell lines.
View article: Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 113K, Supplementary Figure S7. Oral dosing of CB-839 results in high exposure in mouse plasma and is well tolerated in immunocompromised mice.
View article: Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase. CB-839 is a potent, selective, and …
View article: Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 126K, Supplementary Figure S3. TNBC primary tumors and cell lines have elevated glutaminase (GAC) mRNA levels.
View article: Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 126K, Supplementary Figure S3. TNBC primary tumors and cell lines have elevated glutaminase (GAC) mRNA levels.
View article: Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 189K, Supplementary Figure S2. CB-839 has potent anti-proliferative activity in TNBC cells that is associated with selective impairment of glutamine utilization.
View article: Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDf - 136K, Supplementary Figure S1. CB-839 is a non-competitive inhibitor of rHu-GAC.
View article: Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 100K, Supplementary Figure S6. The basal glutamate to glutamine ratio and the fold change in glutamine and glutamate following CB-839 treatment is greater in TNBC cells than receptor-positive cell lines.
View article: Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 246K, Supplementary Materials and Methods.
View article: Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase. CB-839 is a potent, selective, and …
View article: Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 189K, Supplementary Figure S2. CB-839 has potent anti-proliferative activity in TNBC cells that is associated with selective impairment of glutamine utilization.
View article: Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 125K, Supplementary Figure S4. Markers of glutamine utilization are increased in TNBC cell lines relative to receptor-positive cell lines.
View article: Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 85K, Supplementary Figure S5. Induction of apoptotic cell death by CB-839.